Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Century Therapeutics Inc | IPSC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.96 | 04:05:14 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.96 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.28 - 5.51 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.96 | USD |
Century Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 191.86M | 64.82M | - | 2.24M | -136.67M | -2.11 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Century Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IPSC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.86 | 3.565 | 2.75 | 3.03 | 106,665 | 0.10 | 3.50% |
| 1 Month | 4.39 | 4.4278 | 2.75 | 3.53 | 125,892 | -1.43 | -32.57% |
| 3 Months | 4.22 | 5.51 | 2.75 | 4.17 | 215,963 | -1.26 | -29.86% |
| 6 Months | 1.48 | 5.51 | 1.28 | 3.36 | 195,742 | 1.48 | 100.00% |
| 1 Year | 3.02 | 5.51 | 1.28 | 3.14 | 146,073 | -0.06 | -1.99% |
| 3 Years | 19.50 | 32.899 | 1.28 | 10.35 | 146,016 | -16.54 | -84.82% |
| 5 Years | 19.50 | 32.899 | 1.28 | 10.35 | 146,016 | -16.54 | -84.82% |
Century Therapeutics Description
| Century Therapeutics Inc is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with a plays a central role in the production of blood cells in the bone marrow. It is assembling a portfolio of allogeneic iNK and iT cell therapy product candidates across solid tumor and hematological malignancies. |
